Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Sutro Biopharma has disclosed Capital Expenditures across 9 years of filings, most recently posting -$59000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at -$59000.0, up 95.65% year-over-year; the trailing twelve-month figure through Dec 2025 was $11000.0 (down 98.37% YoY), and the FY2025 annual result was $11000.0, down 98.37% from the prior year.
• Capital Expenditures came in at -$59000.0 for Q4 2025 at Sutro Biopharma, down from $47000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.4 million in Q3 2021 to a low of -$12.4 million in Q4 2021.
• The 5-year median for Capital Expenditures is $209000.0 (2023), against an average of $456300.0.
• Across the five-year window, Capital Expenditures tumbled 864.06% in 2021 and surged 387.2% in 2022, its largest moves.
• Sutro Biopharma's Capital Expenditures stood at -$12.4 million in 2021, then soared by 148.99% to $6.1 million in 2022, then plunged by 143.73% to -$2.7 million in 2023, then soared by 48.98% to -$1.4 million in 2024, then jumped by 95.65% to -$59000.0 in 2025.
• The last three Capital Expenditures figures came in at -$59000.0 (Q4 2025), $47000.0 (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.